Next Article in Journal
HTLV-1 Rex Tunes the Cellular Environment Favorable for Viral Replication
Previous Article in Journal
Identification and Comparison of Receptor Binding Characteristics of the Spike Protein of Two Porcine Epidemic Diarrhea Virus Strains
Previous Article in Special Issue
Generation of Recombinant Polioviruses Harboring RNA Affinity Tags in the 5′ and 3′ Noncoding Regions of Genomic RNAs
Article Menu

Export Article

Open AccessReview
Viruses 2016, 8(3), 57;

Therapeutic Use of Native and Recombinant Enteroviruses

Department of Virology, University of Turku, Kiinamyllynkatu 13, 20520 Turku, Finland
Biomaterials and Diagnostics Group, Turku University of Applied Sciences, 20520 Turku, Finland
Author to whom correspondence should be addressed.
Academic Editor: George Belov
Received: 19 October 2015 / Revised: 15 February 2016 / Accepted: 18 February 2016 / Published: 23 February 2016
(This article belongs to the Special Issue Recent Progress in Enterovirus Research)
Full-Text   |   PDF [1159 KB, uploaded 23 February 2016]   |  


Research on human enteroviruses has resulted in the identification of more than 100 enterovirus types, which use more than 10 protein receptors and/or attachment factors required in cell binding and initiation of the replication cycle. Many of these “viral” receptors are overexpressed in cancer cells. Receptor binding and the ability to replicate in specific target cells define the tropism and pathogenesis of enterovirus types, because cellular infection often results in cytolytic response, i.e., disruption of the cells. Viral tropism and cytolytic properties thus make native enteroviruses prime candidates for oncolytic virotherapy. Copy DNA cloning and modification of enterovirus genomes have resulted in the generation of enterovirus vectors with properties that are useful in therapy or in vaccine trials where foreign antigenic epitopes are expressed from or on the surface of the vector virus. The small genome size and compact particle structure, however, set limits to enterovirus genome modifications. This review focuses on the therapeutic use of native and recombinant enteroviruses and the methods that have been applied to modify enterovirus genomes for therapy. View Full-Text
Keywords: CAVATAK™; coxsackievirus A21; enterovirus; poliovirus; IRES; PVS-RIPO; virotherapy CAVATAK™; coxsackievirus A21; enterovirus; poliovirus; IRES; PVS-RIPO; virotherapy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Ylä-Pelto, J.; Tripathi, L.; Susi, P. Therapeutic Use of Native and Recombinant Enteroviruses. Viruses 2016, 8, 57.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top